The first clinical trial of Tolvaptan showed that it was effective in slowing the growth of the total kidney volume (TKV*) and in slowing the decline in eGFR* in ADPKD patients. However, that trial focussed on patients in the early stages of their disease process. Now there is evidence that Tolvaptan also works in patients at the later stages of ADPKD.

The European Medicines Agency (EMA) has recommended extending the marketing authorisation of tolvaptan - known as JINARC.

The European Medicines Agency (EMA) has recommended granting a marketing authorisation to tolvaptan, which now has the brand name: JINARC.

Listen to Dr Donal O'Donoghue, the former National Clinical Director of Kidney Care in England, discuss the Tolvaptan trial and its implications for ADPKD patients. (20 minute video skype chat.)

The Department of Health has asked NICE - the National Institute for Health and Care Excellence - to conduct an appraisal of tolvaptan for treating ADPKD (autosomal dominant polycystic kidney disease). The date of the appraisal meeting will be 1st April 2015.

At the American Society of Nephrology (ASN) meeting on 3 November 2012, Dr Vicente Torrres from the Mayo Clinic, together with research collaborators, reported the results of a 3 year global study known as TEMPO - Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease Outcomes.